Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:RE:RE:RE:Ate'$ next mission

[MrMugsy]

I think the company knows that true value is going to come from an FDA greenlight for OTENA.  Or a partnership with Big Pharma(s) that takes risk out of the Phase 3 but brings big cash into our account.  Either way ... we can then move forward as a serious drug developer.

Just like an FDA greenlight for Biogen's AD drug gave Biogen a market cap increase of $21B (since fallen due to pushback) - that's the kind of excitement us Diehards are expecting here - prorated for the pain & inflammation market.

Everything else is just noise and I'm guessing ATE is focused on partnering for OTENA and all the things that make partnering a success (moving OTENA forward, US market, proving out the IP).
------------

GameChangerBet wrote: There may be some merit to what you're saying. I think managements main focus is the business itself and the the execution of their strategy. Doesn't seem that their primary concern is the stock price or the retail investor.
Personally, I'm looking past all that because I think at the end of it all, if phase 3 ends up being successful and FDA approval is granted, it would be hard to imagine anything but positive free cash flow for many years. 
And in that scenario, they would have several options in terms of pipeline expansion, new drug indications, etc. They will have the financial capacity to proceed aggresively with whatever experiment they want to engage in without having to go to market for financing.
And based on their efforts in securing a US partnership, I don't think we have to wait till the end of phase 3 to see things start to happen.

Forestview wrote: Part of the challenge, GCB, I see is an inability to craft a proper news release that doesn't leave things ambiguous.  Right now, the only news releases are ones that include $$$ figures - retail investors understand that.  But, ATE management has not been able to translate other news releases to something that a retail investor can interpret as a good thing.  I keep going back to the Amalgamation news release (with Holdings that brought the patents over --- retail investors saw this only as further dilution not the positives of all patents being under the same company), and FDA/IND approval.  Both caused the stock price to drop - very bizzare.  I think MikeStock gave this feedback to Dan, but given that we've enlisted a PR company, it's shocking that this is an issue.  Keep holding for now, and hope this management team learns from its mistakes.

GameChangerBet wrote: There are essentially no positive catalysts priced in to the stock. Which means that when those events come to market, the stock will react to it fully and price it in accordingly (contrary to the typical stock market function of buy the rumor, sell the news).
The data from the trials suggests a high probability of a successful outcome.
Nuance agrees. Consider the amount of due diligence they have conducted, which resulted in them paying $20m upfront for a product that doesn't exist on the market yet. 
With all due respect to all retail investors, the amount of wotk Nuance would have done in determining a decision for an investment, is far superior to any work done by retail investors.
They don't make decisions based on stock price, they make decisions based on the actual business, facts and fundamentals.
They put up millions in Antibe.
Keep that in mind next time you feel panic about the stock.

Amigo11 wrote: With about $1.85 in cash per share ,investors are really paying $1.40 per share for all the upside of ATE.As we didn't have any cash per share for most of our existence,a prospective investor hasnt paid this little for all the upsidd in a long time.